Gradient

Gradient is an oral medication containing the active ingredient flunarizine hydrochloride, a calcium channel blocker used for migraine prophylaxis and related neurological conditions. The product is marketed in the European Union and is available by prescription only. While the specific tablet strength and dosage form are not disclosed, the medication is administered orally and belongs to the class of T‑type calcium channel antagonists in clinical practice.

Gradient (flunarizine hydrochloride) is prescribed for several neurological and vascular indications.

- Prevention of migraine attacks. - Management of vertigo associated with vestibular disorders. - Treatment of cerebral vascular disorders such as ischemic episodes. - Adjunct therapy for certain types of chronic headache. - Off‑label use may include prophylaxis of cluster headaches.

Side effects of Gradient vary in frequency and severity, ranging from mild to rare serious reactions.

Common: - Drowsiness or fatigue. - Weight gain. - Dry mouth. - Constipation. - Mood changes such as depression. - Muscle weakness.

Serious: - Extrapyramidal symptoms (e.g., tremor, rigidity). - Severe depression or suicidal thoughts. - Cardiac arrhythmias. - Hepatotoxicity. - Allergic reactions including rash or angioedema.

When considering Gradient therapy, several precautions should be reviewed.

- Assess patient history for depression or mood disorders before initiating treatment. - Use cautiously in individuals with hepatic impairment; monitor liver function. - Evaluate cardiac status, especially in patients with known arrhythmias. - Discuss potential weight gain with patients who have obesity or metabolic concerns. - Avoid abrupt discontinuation to reduce risk of withdrawal symptoms. - Pregnancy and lactation status should be clarified; use only if benefits outweigh risks.

Gradient may interact with other medicines, influencing efficacy or safety.

Avoid: - Concomitant use with other central nervous system depressants (e.g., benzodiazepines, antihistamines) due to additive sedation. - Strong CYP3A4 inhibitors, which can increase flunarizine plasma levels. - Monoamine oxidase inhibitors (MAOIs) because of potential serotonergic effects.

Use with caution: - Antidepressants, particularly SSRIs, may increase risk of mood changes. - Antihypertensive agents, as flunarizine can cause hypotension. - Antipsychotics, especially those affecting dopamine pathways. - Other calcium channel blockers, which may enhance cardiovascular effects.